FM
AMBI

Forward Management’s Ambit Biosciences Corp AMBI Stock Holding History

Forward Management’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-24,615
Closed -$177K – 435
2013
Q3 		$177K Sell
24,615
-32,385
-57% -$429K 0.01% 309
2013
Q2 		$408K Buy
+57,000
New +$408K 0.03% 245

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Forward Management's AMBI Position: Q4 2013 in Review

Forward Management sold out of Ambit Biosciences Corp (AMBI) in Q4 2013, closing a stake of 24,615 shares — an estimated $177K sold.

Forward Management first reported a position in AMBI in Q2 2013 and held it in 2 quarters. The position peaked at $408K in Q2 2013. 35 funds tracked by Wall St. Rank hold AMBI as of Q4 2013.

  • Forward Management reported no remaining Ambit Biosciences Corp position as of Q4 2013 after selling out during the quarter.
  • Forward Management sold 24,615 Ambit Biosciences Corp shares in Q4 2013, an estimated $177K.
  • Forward Management first reported a position in Ambit Biosciences Corp in Q2 2013 and held it in 2 quarters.
  • Forward Management's Ambit Biosciences Corp position peaked at $408K in Q2 2013.
  • 35 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q4 2013.

Based on Forward Management's 13F filing for Q4 2013, filed 31 Jan 2014.